Holen Sie sich die Stockscreener-App
2.35
0.00%
0.00
Vorhandelsmarkt:
2.37
0.02
+0.85%
Schlusskurs vom Vortag:
$2.35
Offen:
$2.35
24-Stunden-Volumen:
3.58M
Relative Volume:
0.63
Marktkapitalisierung:
$799.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.80M
KGV:
-6.7143
EPS:
-0.35
Netto-Cashflow:
$-68.07M
1W Leistung:
+10.33%
1M Leistung:
+19.29%
6M Leistung:
-11.32%
1J Leistung:
-24.92%
1-Tages-Spanne:
$2.32
$2.4088
1-Wochen-Bereich:
$2.15
$2.48
52-Wochen-Spanne:
$1.54
$3.97
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
(415) 754-3517
Adresse
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Vergleichen Sie NUVB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.35 | 724.76M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-03-08 | Eingeleitet | BTIG Research | Buy |
| 2021-03-08 | Eingeleitet | Cowen | Outperform |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
What analysts say about Nuvation Bio Inc. stockTremendous gains - jammulinksnews.com
What drives Nuvation Bio Inc. stock priceTriple-digit profit margins - jammulinksnews.com
Nuvation Bio Inc. Stock Analysis and ForecastPhenomenal investment performance - jammulinksnews.com
Is Nuvation Bio Inc. a good long term investmentConsistently high yield - jammulinksnews.com
Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Breakthrough for IDH1 Mutant Glioma - TipRanks
Will Nuvation Bio Inc. stock benefit from interest rate changesLong Term Low Risk Growth - Newser
Is Nuvation Bio Inc. stock a good hedge against inflationFree Investing Community - Newser
Why Nuvation Bio Inc. stock attracts strong analyst attentionLow Risk Entry Points - beatles.ru
Nuvation Bio's Mysterious 5% Surge: A Deep Dive into the Unseen Drivers - AInvest
What makes Nuvation Bio Inc. stock price move sharplyIntraday Trade Ideas - Newser
How Nuvation Bio Inc. stock performs during market volatilityFree Top Growth Stock Recommendations - Newser
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy - MSN
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Nuvation Bio's 16% Surge: A Deep Dive Into the Unseen Drivers - AInvest
Nuvation Bio's 11% Spike: A Deep Dive into the Unseen Drivers - AInvest
Nuvation Bio’s 7% Surge: A Technical and Market Flow Deep-Dive - AInvest
Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects - Investing.com
Positive week for Nuvation Bio Inc. (NYSE:NUVB) institutional investors who lost 31% over the past year - simplywall.st
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating - MSN
JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans - MSN
Nuvation Bio Inc.(NYSE: NUVB) added to Russell 2500 Growth Index - MarketScreener
Nuvation Bio Inc.(NYSE: NUVB) added to Russell 2000 Growth Index - MarketScreener
Digging for Diamonds in Biotech: Why Insider Buys Signal Opportunity in Nuvation Bio and Ardelyx - AInvest
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nuvation Bio stock rating reiterated at Market Outperform by Citizens JMP - Investing.com South Africa
Nuvation Bio's Taletrectinib Emerges as a Niche Oncology Leader with NCCN Endorsement - AInvest
Nuvation Bio (NUVB) Gains NCCN Endorsement for Taletrectinib in - GuruFocus
Boston Herald - FinancialContent
Nuvation Bio's Mysterious 10% Surge: A Technical & Market Flow Deep Dive - AInvest
Nuvation Bio jumps after insiders purchase shares worth over $1.1M - MSN
Nuvation Bio’s Mysterious 7% Surge: What’s Behind the Volatility? - AInvest
Wealth Enhancement Advisory Services LLC Buys Shares of 10,140 Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Insider Buying: Stacy Markel Acquires 10,000 Shares of Nuvation Bio Inc (NUVB) - GuruFocus
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price - GuruFocus
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Target Price Revised Amid Commercial Shift | NUVB Stock News - GuruFocus
RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk - MarketScreener
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - The Manila Times
Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects - Investing.com India
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio stock holds steady as FDA approves lung cancer drug - Investing.com India
Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment - TipRanks
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):